The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients

Abstract : Background: Different methods have been proposed to analyze adverse events (AEs) associated with targeted therapies. While these AEs lead to dose adjustments for many patients, conventional reporting methods do not take drug administration into consideration. This paper underlines the importance of jointly reporting AEs and drug administration using prevalence, and proposes a complementary approach to reporting. Patients and methods: The prevalence method estimates the probability of progression-free patients being in a particular health state (state 1: AEs with full dose; state 2: AEs with reduced dose; state 3: no AEs with reduced dose) at different time points. To take into account the impact of dose adjustments on efficacy, the weighted prevalence method can be used by assigning utility weights to the different health states. The benefit of these methods was illustrated using data from a phase II trial of regorafenib. Results: Only 4.6% of progression-free patients developed mucositis/stomatitis (grade 2) at 3 months. The prevalence of patients not experiencing this AE but whose dose was reduced or treatment interrupted was 58.1%. The weighted prevalence of the regorafenib toxicity profile and dose reduction was higher in the control arm. Conclusion: This case study confirms the importance of jointly analyzing AEs and drug administration. The weighted prevalence approach is an average score that incorporates the dimension of drug administration into AE assessment. This can be helpful for regulatory agencies as well as for clinicians to evaluate the benefit-risk ratio of therapies in their treatment choice. Clinical trial: NCT01900743.
Document type :
Journal articles
Complete list of metadatas

Cited literature [22 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02093945
Contributor : Christine Dupuis <>
Submitted on : Tuesday, April 9, 2019 - 12:42:20 PM
Last modification on : Thursday, April 11, 2019 - 1:03:10 AM
Long-term archiving on : Wednesday, July 10, 2019 - 1:53:08 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

M Longué, B. Cabarrou, J Wallet, T. Brodowicz, H Roché, et al.. The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients. Annals of Oncology, Oxford University Press (OUP), 2018, 29 (7), pp.1588-1593. ⟨10.1093/annonc/mdy168⟩. ⟨inserm-02093945⟩

Share

Metrics

Record views

40